SEARCH

SEARCH BY CITATION

References

  • 1
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 55867.
  • 2
    Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(Suppl. 1): S3546.
  • 3
    Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 133574.
  • 4
    Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who respond less well? Ann Intern Med 2004; 140: 37081.
  • 5
    Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 63944.
  • 6
    Romero Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 63641.
  • 7
    Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 7585.
  • 8
    Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 2834.
  • 9
    Durante-Mangoni E, Zampino R, Portella G, et al. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin Infect Dis 2009; 10: 439.
  • 10
    Yu ML, Dai CY, Huang JF, et al. Rapid virologic response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 188493.
  • 11
    Poordad FF. Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C. Aliment Pharmacol Ther 2010; 31: 125167.
  • 12
    Askarieh G, Alsiö A, Pugnale P, et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010; 51: 152330.
  • 13
    Romero AI, Lagging M, Westin J, et al. Interferon (IFN)-gamma inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194: 895903.
  • 14
    Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44: 161725.
  • 15
    Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399401.
  • 16
    Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 2009; 41: 11004.
  • 17
    Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 11059.
  • 18
    Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 133845.
  • 19
    Mc Carthy JJ, Li HJ, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 230714.
  • 20
    Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients. Gastroenterology 2010; 139: 1209, e18.
  • 21
    Mangia A, Thompson AJ, Santoro R, et al. IL28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 8217, e1.
  • 22
    Rallón NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24: F239.
  • 23
    Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 157785, e1-3.
  • 24
    Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 5763.
  • 25
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 28993.
  • 26
    Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 246774.
    Direct Link:
  • 27
    Poordad F, McCone J, Bacon BR, et al. Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naïve patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT-2 Final Results. Hepatology 2010; 52(Suppl.): 107A.
  • 28
    Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus PEGINTRON (Peginterferon alfa-2b)/Ribavirin. Hepatology 2010; 52(Suppl.): 430A.
  • 29
    Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 143744.
  • 30
    Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57: 51624.
  • 31
    Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 70349.
  • 32
    Lagging M, Askarieh G, Bochud P, et al. IP-10 is associated with IL28B variation and predicts the first phase decline of HCV RNA and outcome of therapy in chronic hepatitis C. Hepatology 2010; 52(Suppl.): 766A.
  • 33
    Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499509.
  • 34
    Darling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatment serum IP-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2010; 52(Suppl.): 382A.
  • 35
    D’Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100: 150915.
    Direct Link:
  • 36
    Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 16629.
  • 37
    Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 7128.
  • 38
    Mizuta T, Kawaguchi Y, Eguchi Y, et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci 2010; 55: 1839.
  • 39
    Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105: 19707.
  • 40
    Petta S, Cammà C, Di Marco V, et al. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antivir Ther 2009; 14: 6319.
  • 41
    Angelico F, Francioso S, Del Ben M, et al. Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Aliment Pharmacol Ther 2009; 30: 44451.
  • 42
    Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009; 81: 10329.
  • 43
    Merchante N, de los Santos-Gil I, Merino D, et al. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. J Hepatol 2009; 50: 68492.
  • 44
    Cacoub P, Carrat F, Bédossa P, et al. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. Antivir Ther 2009; 14: 83945.
  • 45
    Ryan P, Resino S, Miralles P, et al. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus. J Acquir Immune Defic Syndr 2010; 55: 17681.
  • 46
    Neumann AU, Bain VG, Yoshida EM, et al. Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. Liver Int 2009; 29: 13505.
  • 47
    Durante-Mangoni E, Zampino R, Portella G, et al. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin Infect Dis 2009; 49: 498506.
  • 48
    Bortoletto G, Scribano L, Realdon S, et al. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat 2010; 17: 47580.
  • 49
    Nasta P, Gatti F, Puoti M, et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 2008; 22: 85761.
  • 50
    Grasso A, Malfatti F, De Leo P, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51: 98490.
  • 51
    Lam KD, Bacchetti P, Abbasi F, et al. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology 2010; 52: 3846.